

United States International Trade Commission

Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica

USITC Publication 4038
December 2008



U.S. International Trade Commission

COMMISSIONERS

Shara L. Aranoff, Chairman
Daniel R. Pearson, Vice Chairman
Deanna Tanner Okun
Charlotte R. Lane
Irving A. Williamson
Dean A. Pinkert

**Address all communications to
Secretary to the Commission
United States International Trade Commission
Washington, DC 20436**

U.S. International Trade Commission

Washington, DC 20436

www.usitc.gov

Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica



Publication 4038

December 2008

(This page is intentionally blank)

Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic-Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America-United States Free Trade Agreement Implementation Act, with respect to Costa Rica.

(This page is intentionally blank)

Annex I

Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS.

(1). General note 4 is modified as follows:

(a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries:

Costa Rica

(b). by deleting from subdivision (d) the following subheadings and the country set out opposite each such subheading:

0202.30.02 Costa Rica
0714.10.10 Costa Rica
0714.10.20 Costa Rica
0714.90.45 Costa Rica
0811.90.10 Costa Rica
0811.90.50 Costa Rica
2008.99.13 Costa Rica

(c). by making the following conforming changes to the HTS: for the following subheadings, the Rates of Duty 1-Special subcolumn is modified by deleting the symbol "A*" and inserting an "A" in lieu thereof.

0202.30.02
0714.10.10
0714.10.20
0714.90.45
0811.90.10
0811.90.50
2008.99.13

(2). General note 7 is modified as follows:

(a). by deleting from subdivision (a) the following country from the enumeration of designated beneficiary countries:

Costa Rica

Annex I (continued)

-2-

(b). by adding to the list of countries in subdivision (b)(i)(C) the following country:

Costa Rica

(3). General note 17 is modified as follows:

(a). by deleting from subdivision (a) the following country from the enumeration of designated beneficiary countries:

Costa Rica

(b). by adding to the list of countries in subdivision (e)(ii)(B) the following country:

Costa Rica

(4). Subdivision (a)(iii) of general note 29 is modified by inserting "Costa Rica," before "Dominican Republic".

(5). U.S. note 7(b) to subchapter II of chapter 98 is modified as follows:

(a). by deleting from subdivision (i) the following country from the enumeration of designated beneficiary countries:

Costa Rica

(b). by adding to the list of countries in subdivision (ii)(D)(2) the following country:

Costa Rica

(6). Subchapter XX of chapter 98 is modified as follows:

(a). by deleting from U.S. note 1 the following country from the enumeration of designated beneficiary countries:

Costa Rica

(b). by adding to the list of countries in U.S. note 5(e)(ii) the following country:

Costa Rica

(7). Subchapter XXII of chapter 98 is modified as follows:

(a). by deleting from U.S. note 23 the expression "subheading 9822.05.20" and by inserting in lieu thereof "subheading 9822.05.15 or 9822.05.20";

(b). by adding the following new note in numerical order:

Annex I (continued)

"24. The aggregate quantity of goods of Costa Rica described in U.S. note 23 to this subchapter entered under subheading 9822.05.15 in calendar year 2009 shall not exceed 2,000 metric tons."

(8). U.S. note 25 to subchapter XXII of chapter 98 is modified by inserting the following new paragraph in subdivision (a):

"(v) During the period from January 1, 2009 through December 31, 2009, inclusive, the aggregate quantity of goods described in U.S. note 23 to this subchapter of each party to the Agreement as defined in general note 29(a) enumerated in the table below that is entered under subheading 9822.05.20 shall be limited to the aggregate quantity (set forth in metric tons) specified below for that country:

Costa Rica	11,660"
------------	---------

(9). The following new provisions are inserted in numerical sequence in subchapter XXII of chapter 98, with the material inserted in the columns entitled "Heading/Subheading", "Article Description", and "Rates of Duty 1 Special", respectively:

	:[Goods described in U.S. note 23 to this subchapter:]	:	:	:
	: "Of Costa Rica:	:	:	:
9822.05.15	: Goods provided for in subheading 1701.11.10,	:	:	:
	: 1701.12.10, 1701.91.10, 1701.99.10,	:	:	:
	: 1702.90.10 or 2106.90.44 subject	:	:	:
	: to the quantitative limit specified in	:	:	:
	: U.S. note 24 to this subchapter	:	:	:
		:	:Free (P+)"	:

(10). U.S. note 3 to subchapter I of chapter 99 is modified as follows:

(a). Subdivision (d)(i)(B) is amended by deleting "to El Salvador under (d)(v) of this note" and by inserting in lieu there of "to El Salvador and to Costa Rica under subdivisions (d)(v) and (d)(vi), respectively, of this note".

(b). The following new subdivision (d)(vi) is inserted at the end of such note:

"(vi) The aggregate quantity allocated to Costa Rica of the base quantity set forth in subdivision (d)(i) of this note in any calendar year shall not exceed the metric equivalent of 31,000,000 gallons."

(11). The last sentence of U.S. note 1 to subchapter IV of chapter 99 is modified by adding ", Costa Rica " at the end of the list of countries.

(12). The U.S. notes and provisions of subchapter XV of chapter 99 are modified as set forth below.

(a). U.S. note 4 is modified as follows:

(i). by inserting "Costa Rica," immediately before "Dominican Republic," in the first and third sentences of text; and

Annex I (continued)

-4-

(ii). by inserting in the table in such note the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u> (metric tons)	<u>2012</u>	<u>2013</u>	
"Costa Rica	12,042	12,544	13,046	13,548	14,050"	
	<u>2014</u>	<u>2015</u>	<u>2016</u> (metric tons)	<u>2017</u>	<u>2018</u>	<u>2019</u>
"Costa Rica	14,552	15,054	15,556	16,058	16,560	17,062"

(b). U.S. note 5 is modified as follows:

(i). in subdivision (a) and (b), by deleting "El Salvador, Guatemala, Honduras or Nicaragua" in the first and second sentence and inserting "Costa Rica, El Salvador, Guatemala, Honduras or Nicaragua" in lieu thereof;

(ii). in subdivision (a), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u> (liters)		
"Costa Rica	471,687	495,271	520,035"		
	<u>2012</u>	<u>2013</u>	<u>2014</u> (liters)	<u>2015</u>	<u>2016</u>
"Costa Rica	546,037	573,339	602,006	632,106	663,711"
	<u>2017</u>	<u>2018</u>	<u>2019</u> (liters)	<u>2020</u>	<u>2021</u>
"Costa Rica	696,897	731,741	768,329	806,745	847,082"
	<u>2022</u>	<u>2023</u>	<u>2024</u> (liters)		
"Costa Rica	889,436	933,908	980,604"		

(iii). in subdivision (b), by inserting in the table in such subdivision the following country and the quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u> (liters)		
"Costa Rica	141,506	148,581	156,010"		
	<u>2012</u>	<u>2013</u>	<u>2014</u> (liters)	<u>2015</u>	<u>2016</u>
"Costa Rica	163,811	172,002	180,602	189,632	199,113"
	<u>2017</u>	<u>2018</u>	<u>2019</u> (liters)	<u>2020</u>	<u>2021</u>
"Costa Rica	209,069	219,522	230,499	242,024	254,125"
	<u>2022</u>	<u>2023</u>	<u>2024</u> (liters)		
"Costa Rica	266,831	280,172	294,181"		

Annex I (continued)

-5-

(c). U.S. note 6 is modified as follows:

(i). in subdivision (a) and (b), by inserting "Costa Rica," immediately before "El Salvador," at each instance;

(ii). in subdivision (a), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
			(metric tons)		
"Costa Rica	58	61	64"		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
			(metric tons)		
"Costa Rica	67	70	74	78	81"
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
			(metric tons)		
"Costa Rica	86	90	94	99	104"
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
			(metric tons)		
"Costa Rica	109	115	120"		

(iii). in subdivision (b), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
			(metric tons)		
"Costa Rica	17	18	19"		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
			(metric tons)		
"Costa Rica	20	21	22	23	24"
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
			(metric tons)		
"Costa Rica	26	27	28	30	31"
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
			(metric tons)		
"Costa Rica	33	34	36"		

(d). The following new U.S. note is inserted in numerical sequence:

"7. (a) The aggregate quantity of goods described in U.S. note 2 to this subchapter of Costa Rica entered under subheading 9915.04.20 in any calendar year shall not exceed the quantity specified below for that year.

<u>Year</u>	<u>Quantity</u>	<u>Year</u>	<u>Quantity</u>	<u>Year</u>	<u>Quantity</u>
	(metric tons)		(metric tons)		(metric tons)
2009	58	2014	74	2019	94
2010	61	2015	78	2020	99
2011	64	2016	81	2021	104
2012	67	2017	86	2022	109
2013	70	2018	90	2023	115
				2024	120

Annex I (continued)

-6-

Beginning in calendar year 2025, the quantitative limitations set forth in this subdivision shall cease to apply to such goods of Costa Rica.

- (b) The aggregate quantity of goods described in U.S. note 2 to this subchapter of Costa Rica entered under subheadings 9915.04.21 through 9915.04.24 in any calendar year shall not exceed the quantity specified below for that year.

<u>Year</u>	<u>Quantity</u> (metric tons)	<u>Year</u>	<u>Quantity</u> (metric tons)	<u>Year</u>	<u>Quantity</u> (metric tons)
2009	17	2014	22	2019	28
2010	18	2015	23	2020	30
2011	19	2016	24	2021	31
2012	20	2017	26	2022	33
2013	21	2018	27	2023	34
				2024	36

Beginning in calendar year 2025, the quantitative limitations set forth in this subdivision shall cease to apply to such goods of Costa Rica.

Unless earlier modified or terminated, this note, subheadings 9915.04.20 through 9915.04.28, any intervening text and the immediate superior text thereto shall be deleted from the tariff schedule at the close of December 31, 2025.”

- (e). U.S. note 8 is modified as follows:

(i). in subdivisions (a) and (b), by inserting “Costa Rica,” immediately before “Dominican Republic,” in the first sentence of each such subdivision; and by modifying the second sentence of each such subdivision to read “Costa Rica, Dominican Republic, El Salvador, Guatemala or Nicaragua”;

(ii). in subdivision (a), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
			(metric tons)		
“Costa Rica	174	182	191”		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
			(metric tons)		
“Costa Rica	201	211	222	233	244”
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
			(metric tons)		
“Costa Rica	257	269	283	297	312”
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
			(metric tons)		
“Costa Rica	327	344	361”		

Annex I (continued)

-7-

(iii). in subdivision (b), by inserting in the table in such subdivision the following country and the quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
			(metric tons)		
"Costa Rica	52	55	57"		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
			(metric tons)		
"Costa Rica	60	63	67	70	73"
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
			(metric tons)		
"Costa Rica	77	81	85	89	94"
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
			(metric tons)		
"Costa Rica	98	103	108"		

(f). U.S. note 10 is modified as follows:

(i). in subdivision (a), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
			(metric tons)		
"Costa Rica	347	365	383"		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
			(metric tons)		
"Costa Rica	402	422	443	465	489"
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
			(metric tons)		
"Costa Rica	513	539	566	594	624"
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
			(metric tons)		
"Costa Rica	655	688	722"		

Annex I (continued)

-8-

(ii). in subdivision (b), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
		(metric tons)			
"Costa Rica	104	110	115"		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
		(metric tons)			
"Costa Rica	121	127	133	140	147"
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
		(metric tons)			
"Costa Rica	154	162	170	178	187"
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
		(metric tons)			
"Costa Rica	196	206	217"		

(g). U.S. note 14 is modified as follows:

(i). in subdivision (a), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u>	<u>2011</u>		
		(liters)			
"Costa Rica	112,390	118,010	123,910"		
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
		(liters)			
"Costa Rica	130,106	136,611	143,442	150,614	158,144"
	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
		(liters)			
"Costa Rica	166,052	174,354	183,072	192,226	201,837"
	<u>2022</u>	<u>2023</u>	<u>2024</u>		
		(liters)			
"Costa Rica	211,929	222,525	233,651"		

Annex I (continued)

-9-

(ii). in subdivision (b), by inserting in the table in such subdivision the following country and the associated quantities for such country under the specified years:

	<u>2009</u>	<u>2010</u> (liters)	<u>2011</u>		
"Costa Rica	33,717	35,403	37,173"		
	<u>2012</u>	<u>2013</u> (liters)	<u>2014</u>	<u>2015</u>	<u>2016</u>
"Costa Rica	39,032	40,983	43,033	45,184	47,443"
	<u>2017</u>	<u>2018</u> (liters)	<u>2019</u>	<u>2020</u>	<u>2021</u>
"Costa Rica	49,816	52,306	54,922	57,668	60,551"
	<u>2022</u>	<u>2023</u> (liters)	<u>2024</u>		
"Costa Rica	63,579	66,758	70,095"		

(h). The following new U.S. note is inserted in numerical sequence:

"16. Apparel goods of Costa Rica.

- (a) Subject to the provisions of subdivision (c) of this note, the rate of duty provided for in subheading 9915.62.05 in the "Special" subcolumn of rates of duty column 1 shall apply to goods of Costa Rica enumerated in subdivision (b) of this note, in an aggregate annual quantity not to exceed 500,000 square meters equivalent (SME) in calendar years 2009 through 2018. Subheading 9915.62.05 applies to wool apparel goods described in this note if the goods are both cut and sewn or otherwise assembled in the territory of Costa Rica and meet all applicable conditions for preferential tariff treatment set forth in general note 29 to the tariff schedule (other than that they are originating goods), provided that such goods comply with the requirements set forth in chapter rules 1, 3, 4 and 5 for chapter 62 of such general note for originating goods.
- (b) The following apparel goods, not knitted or crocheted, containing 36 percent or more by weight of wool or subject to wool restraints, provided for in heading 6203 or 6204, shall receive the tariff treatment set forth in such subheading 9915.62.05:
- (i) suits for men or boys classified in subheading 6203.11.15, 6203.11.30, 6203.11.60, 6203.11.90, 6203.12.10, 6203.19.20, 6203.19.90 or 6203.29.10;
 - (ii) suit-type jackets and blazers for men or boys classified in subheading 6203.23.00, 6203.29.10, 6203.29.15, 6203.31.50, 6203.31.90, 6203.33.10, 6203.39.10 or 6203.39.90;
 - (iii) trousers, breeches and shorts for men or boys classified in subheading 6203.23.00, 6203.29.10, 6203.29.15, 6203.41.05, 6203.41.12, 6203.41.18, 6203.43.30, 6203.49.20 or 6203.49.80;
 - (iv) suits for women or girls classified in subheading 6204.11.00, 6204.13.10, 6204.19.10 or 6204.19.80;
 - (v) suit-type jackets and blazers for women or girls classified in subheading 6204.31.10, 6204.31.20, 6204.33.40, 6204.39.20 or 6204.39.80;
 - (vi) skirts for women or girls classified in subheading 6204.21.00, 6204.23.00, 6204.29.40, 6204.51.00, 6204.53.20, 6204.59.20 or 6204.59.40; or
 - (vii) trousers, breeches and shorts for women or girls classified in subheading 6204.21.00, 6204.23.00, 6204.29.40, 6204.61.10, 6204.61.90, 6204.63.25, 6204.69.20, 6204.69.60 or 6204.69.90.
- (c) The rate of duty provided for in subheading 9915.62.15 in the "Special" subcolumn of rates of duty column 1 shall apply to goods of Costa Rica enumerated in subdivision (d) of this note, in an aggregate annual quantity not to exceed 500,000 square meters equivalent (SME) in calendar years 2009 through 2018. Subheading 9915.62.15 applies to wool apparel goods described in this note if the goods are both cut and sewn or

Annex I (continued)

-10-

otherwise assembled in the territory of Costa Rica, and meet all applicable conditions for preferential tariff treatment set forth in general note 29 to the tariff schedule other than that they be originating goods. Goods that could qualify for preferential treatment under both subdivision (a) of this note and this subdivision shall be imported under and counted first toward the limit described in this subdivision, until such limit is reached, and then shall be imported under and counted toward the limit established in subdivision (a).

- (d) The following apparel goods made from fabric of wool (except fabric of carded wool, or made from wool yarn having an average fiber diameter of less than or equal to 18.5 microns) shall receive the tariff treatment set forth in such subheading 9915.62.15:
- (i) suits for men or boys classified in subheading 6203.11.30 or 6203.11.90;
 - (ii) suit-type jackets and blazers for men or boys classified in subheading 6203.29.15 or 6203.31.90;
 - (iii) waistcoats (vests) for men or boys classified in subheading 6203.29.15 or 6211.39.05;
 - (iv) trousers and breeches for men or boys classified in subheading 6203.29.15, 6203.41.05 or 6203.41.18;
 - (v) suits for women or girls classified in subheading 6204.11.00;
 - (vi) suit-type jackets and blazers for women or girls classified in subheading 6204.21.00, 6204.31.10 or 6204.31.20;
 - (vii) waistcoats (vests) for women or girls classified in subheading 6204.21.00 or 6211.41.00;
 - (viii) skirts for women or girls classified in subheading 6204.21.00 or 6204.51.00; or
 - (ix) trousers and breeches for women or girls classified in subheading 6204.21.00, 6204.61.10 or 6204.61.90.
- (e) For purposes of determining the quantity of square meter equivalents (SME) to be charged against the aggregate quantity specified in this subdivision, the conversion factors listed in *Correlation: U.S. Textile and Apparel Category System with the Harmonized Tariff Schedule of the United States of America 2003*, U.S. Department of Commerce, Office of Textiles and Apparel, or successor publication, shall apply.
- (f) Unless earlier modified or terminated, this note and subheadings 9915.62.05 and 9915.62.15 shall be deleted from the tariff schedule at the close of December 31, 2019.”

(i). The following new U.S. note is inserted in numerical sequence:

“17. Mastectomy swimsuits of Costa Rica.

- (a) The aggregate quantity of goods described in U.S. note 2 to this subchapter of Costa Rica entered under subheadings 9915.61.01 or 9915.61.02 in any calendar year shall not exceed the quantity specified below for that year:

<u>Year</u>	<u>Quantity</u> (Square Meter Equivalents)	<u>Year</u>	<u>Quantity</u> (Square Meter Equivalents)
2009	100,000	2014	133,823
2010	106,000	2015	133,823
2011	112,360	2016	133,823
2012	119,102	2017	133,823
2013	126,248	2018	133,823

Subheadings 9915.61.01 and 9915.61.02 shall apply only to women’s knitted or crocheted swimwear (provided for in subheading 6112.41.00 or 6112.49.00) specially designed to accommodate post-mastectomy breast prostheses, containing two full size interior pockets with side openings, two preformed cups, a supporting elastic band below the breast and vertical center stitching to separate the two pockets, if such imported goods are both cut or knit to shape and sewn or otherwise assembled in the territory of Costa Rica and meet the applicable conditions for preferential tariff treatment set forth in general note 29 to the tariff schedule other than that they be originating goods.

Annex I (continued)

-11-

- (b) For purposes of determining the quantity of square meter equivalents (SME) to be charged against the aggregate quantity specified in this subdivision, the conversion factors listed in *Correlation: U.S. Textile and Apparel Category System with the Harmonized Tariff Schedule of the United States of America 2003*, U.S. Department of Commerce, Office of Textiles and Apparel, or successor publication, shall apply.
- (c) Unless earlier modified or terminated, this note, subheadings 9915.61.01 and 9915.61.02, and the immediate superior text thereto shall be deleted from the tariff schedule at the close of December 31, 2019.”

(j). The superior text to subheading 9915.02.05 reading “Of Dominican Republic, El Salvador, Honduras or Nicaragua:” is modified to read “Of Costa Rica, Dominican Republic, El Salvador, Honduras or Nicaragua:”.

(k). The superior text to subheading 9915.04.01 reading “Of El Salvador, Guatemala, Honduras or Nicaragua:” is modified to read “Of Costa Rica, El Salvador, Guatemala, Honduras or Nicaragua:”.

(l). The superior text to subheading 9915.04.05 reading “Of El Salvador or Honduras:” is modified to read “Of Costa Rica, El Salvador or Honduras:”.

(m). The following new heading is inserted in numerical sequence in such subchapter, with the material inserted in the columns entitled “Heading/Subheading”, “Article Description”, and “Rates of Duty 1 Special”, respectively:

	: [Goods described in U.S. note 2 to this subchapter:]	:	:	:
	: “Of Costa Rica:	:	:	:
	: Goods provided for in subheading 0402.10.50,	:	:	:
	: 0402.21.25, 0402.21.50, 0403.90.45,	:	:	:
	: 0403.90.55, 0404.10.90, 2309.90.28 or	:	:	:
	: 2309.90.48:	:	:	:
9915.04.20	: Subject to the quantitative limits specified	:	:	:
	: in U.S. note 7(a) to this subchapter	:	:	: Free (P+)
	: Subject to the quantitative limits specified	:	:	:
	: U.S. note 7(b) to this subchapter:	:	:	:
9915.04.21	: Goods provided for in subheading	:	:	:
	: 0402.10.50 or 0402.21.25	:	:	: [See Annex IIC] (P+)
9915.04.22	: Goods provided for in subheading	:	:	:
	: 0402.21.50 or 0403.90.55	:	:	: [See Annex IIC] (P+)
9915.04.23	: Goods provided for in subheading	:	:	:
	: 0403.90.45 or 0404.10.90	:	:	: [See Annex IIC] (P+)
9915.04.24	: Goods provided for in subheading	:	:	:
	: 2309.90.28 or 2309.90.48	:	:	: [See Annex IIC] (P+)

Annex I (continued)

-12-

	: [Goods...:]	:	:	:
	: [Of Costa Rica:]	:	:	:
	: [Goods...:]	:	:	:
	: Other:	:	:	:
9915.04.25	: Goods provided for in subheading	:	:	:
	: 0402.10.50 or 0402.21.25	:	: [See Annex IIC] (P+)	:
	:	:	:	:
9915.04.26	: Goods provided for in subheading	:	:	:
	: 0402.21.50 or 0403.90.55	:	: [See Annex IIC] (P+)	:
	:	:	:	:
9915.04.27	: Goods provided for in subheading	:	:	:
	: 0403.90.45 or 0404.10.90	:	: [See Annex IIC] (P+)	:
	:	:	:	:
9915.04.28	: Goods provided for in subheading	:	:	:
	: 2309.90.28 or 2309.90.48	:	: [See Annex IIC] (P+)"	:

(n). The superior text to subheading 9915.04.30 reading “Of Dominican Republic, El Salvador, Guatemala or Nicaragua.” is modified to read “Of Costa Rica, Dominican Republic, El Salvador, Guatemala or Nicaragua.”.

(o). The following new headings are inserted in numerical sequence in such subchapter, with the material inserted in the columns entitled “Heading/Subheading”, “Article Description”, and “Rates of Duty 1 Special”, respectively:

“9915.62.05	: Apparel goods of Costa Rica, not knitted or crocheted,	:	:	:
	: containing 36 percent or more by weight of wool or	:	:	:
	: subject to wool restraints, the foregoing described in	:	:	:
	: U.S. note 16(b) to this subchapter and imported in aggregate	:	:	:
	: annual quantities not to exceed the quantities set	:	:	:
	: forth in U.S. note 16(a) to this subchapter	:	: Free	:
	:	:	:	:
9915.62.15	: Apparel goods of Costa Rica made from wool fabric (except	:	:	:
	: fabric of carded wool, or made from wool yarn having an	:	:	:
	: average fiber diameter of not more than 18.5 microns),	:	:	:
	: the foregoing described in U.S. note 16(d) to this sub-	:	:	:
	: chapter and imported in aggregate annual quantities not to	:	:	:
	: exceed the quantities set forth in U.S. note 16(c) to this	:	:	:
	: subchapter	:	: Free”	:

(p). The following new heading is inserted in numerical sequence in such subchapter, with the material inserted in the columns entitled “Heading/Subheading”, “Article Description”, and “Rates of Duty 1 Special”, respectively:

	: “Women’s knit mastectomy swimwear of Costa Rica	:	:	:
	: (provided for in subheading 6112.41.00 or 6112.49.00),	:	:	:
	: the foregoing described in U.S. note 17 to this subchapter	:	:	:
	: and imported in aggregate annual quantities not to exceed	:	:	:
	: the quantities set forth in U.S. note 17 to this subchapter:	:	:	:
9915.61.01	: Goods provided for in HTS 6112.41.00 described in	:	:	:
	: U.S. note 17 to this subchapter	:	: Free	:
	:	:	:	:
9915.61.02	: Goods provided for in HTS 6112.49.00 described in	:	:	:
	: U.S. note 17 to this subchapter	:	: Free”	:

Annex II

Modifications to the Rates of Duty 1-Special Subcolumn of the Harmonized Tariff Schedule of the United States (HTS)

Section A. Effective with respect to originating goods under the terms of general note 29 to the tariff schedule that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009:

(1). Additional U.S. note 4 to chapter 9 is modified by inserting “ Costa Rica,” alphabetically into the list of countries.

(2). The Rates of Duty 1-Special subcolumn is modified by inserting in such subcolumn, for each of the subheadings listed in Column A below, the phrase in Column B opposite such subheading.

<u>Column A</u>	<u>Column B</u>
0402.10.50	See 9915.04.20, 9915.04.21, 9915.04.25 (P+)
0402.21.25	See 9915.04.20, 9915.04.21, 9915.04.25 (P+)
0402.21.50	See 9915.04.20, 9915.04.22, 9915.04.26 (P+)
0403.90.45	See 9915.04.20, 9915.04.23, 9915.04.27 (P+)
0403.90.55	See 9915.04.20, 9915.04.22, 9915.04.26 (P+)
0404.10.90	See 9915.04.20, 9915.04.23, 9915.04.27 (P+)
1701.11.10	See 9822.05.15 (P+)
1701.12.10	See 9822.05.15 (P+)
1701.91.10	See 9822.05.15 (P+)
1701.99.10	See 9822.05.15 (P+)
1702.90.10	See 9822.05.15 (P+)
2106.90.44	See 9822.05.15 (P+)
2309.90.28	See 9915.04.20, 9915.04.24, 9915.04.28 (P+)
2309.90.48	See 9915.04.20, 9915.04.24, 9915.04.28 (P+)

Annex II (continued)

-3-

Section B(ii). Effective with respect to goods of a party to the Agreement as defined in general note 29(a) to the tariff schedule that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2016, and on January 1 of each of the successive years, for each of the enumerated subheadings in the following table, the Rates of Duty 1-Special subcolumn in the HTS is modified (i) by inserting in such subcolumn for each subheading the rate of duty specified for such subheading in the January 1, 2016 column followed by the symbol "P+" in parentheses, and (ii) for each of the subsequent dated columns the rates of duty that are followed by the symbol "P+" in parentheses are deleted and the rates of duty for such dated column are inserted in such subheadings in lieu thereof for the years 2016 through 2025. For staging of the enumerated subheadings in this table prior to 2016 see section B(i) of this Annex.

HTS Subheading	Base Rate	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
9915.04.21	86.5¢/kg	77.8¢/kg	69.2¢/kg	60.5¢/kg	51.9¢/kg	43.2¢/kg	34.6¢/kg	25.9¢/kg	17.3¢/kg	8.6¢/kg	Free
9915.04.22	\$1.092/kg	98.2¢/kg	87.3¢/kg	76.4¢/kg	65.5¢/kg	54.6¢/kg	43.6¢/kg	32.7¢/kg	21.8¢/kg	10.9¢/kg	Free
9915.04.23	87.6¢/kg	78.8¢/kg	70¢/kg	61.3¢/kg	52.5¢/kg	43.8¢/kg	35¢/kg	26.2¢/kg	17.5¢/kg	8.7¢/kg	Free
9915.04.24	80.4¢/kg + 6.4%	72.3¢/kg + 5.7%	64.3¢/kg + 5.1%	56.2¢/kg + 4.4%	48.2¢/kg + 3.8%	40.2¢/kg + 3.2%	32.1¢/kg + 2.5%	24.1¢/kg + 1.9%	16¢/kg + 1.2%	8¢/kg + 0.6%	Free
9915.04.25	86.5¢/kg	86.5¢/kg	86.5¢/kg	86.5¢/kg	86.5¢/kg	75.6¢/kg	73.5¢/kg	71.3¢/kg	51.9¢/kg	47.5¢/kg	Free
9915.04.26	\$1.092/kg	\$1.092/kg	\$1.092/kg	\$1.092/kg	\$1.092/kg	95.5¢/kg	92.8¢/kg	90¢/kg	65.5¢/kg	60¢/kg	Free
9915.04.27	87.6¢/kg	87.6¢/kg	87.6¢/kg	87.6¢/kg	87.6¢/kg	76.6¢/kg	74.4¢/kg	72.2¢/kg	52.5¢/kg	48.1¢/kg	Free
9915.04.28	80.4¢/kg + 6.4%	80.4¢/kg + 6.4%	80.4¢/kg + 6.4%	80.4¢/kg + 6.4%	80.4¢/kg + 6.4%	70.3¢/kg + 5.6%	68.3¢/kg + 5.4%	66.3¢/kg + 5.2%	48.2¢/kg + 3.8%	44.2¢/kg + 3.5%	Free

Annex II (continued)

-4-

Section C. Effective with respect to goods of a party to the Agreement as defined in general note 29(a) to the tariff schedule that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2025, the HTS is modified as follows:

The Rates of Duty 1-Special subcolumn is modified by, for the following subheadings, deleting the “(P+)” and the phrase preceding such symbol:

0402.10.50

0402.21.25

0402.21.50

0403.90.45

0403.90.55

0404.10.90

2309.90.28

2309.90.48

ANNEX III

TECHNICAL RECTIFICATIONS TO THE PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE OF THE UNITED STATES

Effective with respect to goods entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, Table 1 of the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States is modified as provided herein:

(1) by inserting into such Table 1 the Chemical Abstracts Service (CAS) Registry Numbers set forth in the second column in the tabulation below after the corresponding International Non-proprietary Names (INN) set forth in the first column in such tabulation:

INN	CAS No.
ALMAGODRATE	103371-30-8
ARDACIN	117742-13-9
BEPHENIUM HYDROXYNAPHTHOATE	3818-50-6
BICROMAB	138783-13-8
CANGRELOR	163706-06-7
CARBAZOCHROME SODIUM	51460-26-5
CELUCLORAL	302-17-0
CERTOPARIN SODIUM	67330-25-0
CLORAMFENICOL PANTOTENATE COMPLEX	31342-36-6
CROBENETINE	221019-25-6
DIMETHYLTUBOCURARINIUM CHLORIDE	35-57-6
DORLIMOMAB ARITOX	122722-03-6
EPITUMOMAB	263547-71-3
ERBULOZOLE	124784-31-2
FERRIC (59 FE) CITRATE INJECTION	2238-05-8
FIGOPITANT	502422-74-4
FULADECTIN	205537-83-3
GANSTIGMINE	457075-21-7
MINOLTEPARIN SODIUM	9041-08-1
MOROCTOCOG ALFA	284036-24-4
MUROMONAB CD3	140608-64-6
NADROPARIN CALCIUM	37270-89-6
OZOGAMICIN	400046-53-9
PARNAPARIN SODIUM	9041-08-7
PENTOSAN POLYSULFATE SODIUM	140207-93-8
PITRAKINRA	1017276-51-5
PROPAGERMANIUM	12758-40-6
REPAGERMANIUM	12758-40-6
REVIPARIN SODIUM	103-16-2
SEVIRUMAB	138660-96-5
SOLIMASTAT	226072-63-5
SOMETRIBOVE	102744-97-8
SOMETRIPOR	102733-72-2
SULAMSEROD	219757-90-1
TENDAMISTAT	86596-25-0
THYMOSTIMULIN	78113-36-7
TINZAPARIN SODIUM	9041-08-1
TUVIRUMAB	148189-70-2
UROFOLLITROPIN	97048-13-0
ZOTICASONE	678160-57-1

Annex III (continued)

-2-

(2) by deleting from such Table 1 the following INN and any associated CAS registry numbers:

ABAPERIDONUM	AMEDIPASUM	ATRASENTANUM
ABATACEPTUM	AMELUBANTUM	AVANAFILUM
ABETIMUSUM	AMIGLUMIDUM	AVASIMIBUM
ABRINEURINUM	AMOTOSALENUM	AVISCUMINUM
ACIDUM SALCAPROZICUM	AMPRENAVIRUM	AVOSENTAN
ACIDUM SALCLOBUZICUM	ANATIBANTUM	AXITROMUM
ACIDUM LIDADRONICUM	ANATUMOMABUM MAFENATOXUM	AXOMADOLUM
ACIDUM GADOCOLETICUM	ANCESTIMUM	BALAGLITAZONUM
ACIDUM CARGLUMICUM	ANCRIVIROCUM	BALICATIBUM
ACIDUM CALOXETICUM	ANECORTAVUM	BAMIRASTINUM
ACIDUM ARUNDICUM	ANIDULAFUNGINUM	BANOXANTRONUM
ACOLBIFENUM	ANISPERIMUSUM	BAPINEUZUMAB
ACOTIAMIDUM	ANTITHROMBIN ALFA	BARIXIBATUM
ADALIMUMABUM	APAZIQUONUM	BARUSIBANUM
ADARGILEUKINUM ALFA	APIXABAN	BATABULINUM
ADECATUMUMABUM	APLINDORUM	BAZEDOXYFENUM
ADEKALANTUM	APOLIZUMABUM	BECAMPANELUM
ADROGOLIDUM	APRATASTAT	BECATECARINUM
AFELETECANUM	APREPITANTUM	BECOCALCIDIOLUM
AGALSIDASUM ALFA	APRINOCARSENUM	BEFETUPITANTUM
AGALSIDASUM BETA	ARASERTACONAZOLE	BELATACEPT
ALAGEBRIUM CHLORIDUM	ARDENERMINUM	BELIMUMABUM
ALAMIFOVIRUM	ARFORMOTEROLUM	BELOTECANUM
ALBACONAZOLUM	ARIMOCLOMOLUM	BEMINAFILUM
ALEFACEPTUM	ARMODAFINILUM	BEMOTRIZINOLUM
ALEMCINALUM	ARTEMIFONUM	BERTILIMUMABUM
ALEMTUZUMABUM	ARTEMOTILUM	BESILESOMABUM
ALFATRADIOLUM	ARTENIMOLUM	BEVACIZUMABUM
ALFIMEPRASUM	ARZOXYFENUM	BEXAROTENUM
ALGLUCOSIDASUM ALFA	ASCORBYLUM GAMOLENAS	BEXLOSTERIDUM
ALICAFORSENUM	ASELIZUMABUM	BIFARCEPTUM
ALILUSEMUM	ASENAPINUM	BIFEPRUNOXUM
ALISKIRENUM	ASOPRISNILI ECAMAS	BILASTINUM
ALITRETINOINUM	ASOPRISNILUM	BIMATOPROSTUM
ALTINICLINUM	ATACIGUATUM	BIMOSOAMOSUM
ALVAMELINUM	ATAQUIMASTUM	BINETRAKINUM
ALVIMOPANUM	ATAZANAVIRUM	BINODENOSONUM
ALVOCIDIBUM	ATILMOTINUM	BISOCTRIZOLUM
AMBRISENTANUM	ATOCALCITOLUM	BIVATUZUMABUM
AMDOXOVIRUM	ATOROLIMUMABUM	BORTEZOMIBUM

Annex III (continued)

-3-

BRIVARACETAM	CRIDANIMODUM	DIBOTERIMINUM ALFA
BROSTALLICINUM	CROBENETINUM	DIFLOMOTECANUM
BULAQUINUM	DABIGATRANUM	DIQUAFOSOLUM
CADROFLOXACINUM	DABIGATRANUM ETEXILATUM	DIRLOTAPIDUM
CALCOBUTROLUM	DABUZALGRONUM	DISERMOLIDUM
CALDARETUM	DACINOSTATUM	DISUFENTONUM NATRICUM
CANERTINIBUM	DAGLUTRILUM	DOFEQUIDARUM
CANFOSFAMIDUM	DALBAVANCINUM	DONITRIPTANUM
CANGRELORUM	DAPICLERMINE	DORAMAPIMODUM
CANTUZUMABUM MERTANSINUM	DAPIVIRINUM	DORANIDAZOLUM
CAPRAVIRINUM	DARBEPOETINUM ALFA	DORIPENEMUM
CAPROMORELINUM	DARBUFELONUM	DOXERCALCIFEROLUM
CARABERSATUM	DARUNAVIRUM	DROTRECOGINUM ALFA (ACTIVATUM)
CARICOTAMIDE	DARUSENTANUM	ECALCIDENUM
CARMOTEROLUM	DASANTAFILUM	ECALLANTIDE
CASPOFUNGINUM	DAVASAICINUM	ECOPIPAMUM
CATUMAXOMAB	DAXALIPRAMUM	ECOPLADIBUM
CEFMATILENUM	DEFERASIROXUM	ECRAPROSTUM
CEFOVECINUM	DEFERITRINUM	ECROMEXIMABUM
CEFTOBIPROLUM MEDOCARILUM	DEFOSLIMODUM	ECULIZUMABUM
CEFTOBIPROLUM	DEGARELIXUM	EDAGLITAZONUM
CELECOXIBUM	DELIGOPARINUM NATRICUM	EDIFOLGIDUM
CERTOLIZUMABUM PEGOLUM	DELMITIDUM	EDODEKINUM ALFA
CETHROMYCINUM	DELUCEMINUM	EDONENTANUM
CETILISTATUM	DENUFOSOLUM	EDOTECARINUM
CETUXIMABUM	DEPELESTATUM	EDOTREOTIDUM
CILENGITIDUM	DEPREOTIDUM	EDRATIDUM
CILOMILASTUM	DERACOXIBUM	EDRONOCAINUM
CILUPREVIRUM	DERSALAZINUM	EFALIZUMABUM
CIMICOXIBUM	DESLORATADINUM	EFAPROXIRALUM
CINACALCETUM	DESMOTEPLASUM	EFIPLADIBUM
CINTREDEKINUM BESUDOTOXUM	DESVENLAFAXINUM	EFLUCIMIBUM
CIPEMASTATUM	DETIVICICLOVIRUM	EGANOPROSTUM
CIPRALISANTUM	DEUTOLPERISONUM	EGLUMETADUM
CLAMIKALANTUM	DEXBUDESONIDUM	ELAROFIBANUM
CLAZOSENTANUM	DEXLANSOPRAZOLE	ELOMOTECANUM
CLOFARABINUM	DEXMETHYLPHENIDATUM	ELSILIMOMABUM
COLURACETAMUM	DEXTIOPRONINUM	ELVUCITABINUM
CONIVAPTANUM	DEXTOFISOPAMUM	ELZASONANUM
CORIFOLLITROPINUM ALFA	DIANICLINE	EMBECONAZOLUM

Annex III (continued)

-4-

EMFILERMINUM	ETRICIGUATUM	FRAKEFAMIDUM
EMIVIRINUM	EUFAUSERASUM	FRESELESTATUM
EMODEPSIDUM	EVERNIMICINUM	FULADECTIN
EMTRICITABINUM	EVEROLIMUSUM	GADODENTERATUM
ENECADINUM	EXENATIDUM	GADOFOSVESETUM
ENFUVIRTIDUM	EXATECANUM ALIDEXIMERUM	GADOMELITOLUM
ENIPORIDUM	EXATECANUM	GALARUBICINUM
ENRASENTANUM	EXBIVIRUMABUM	GALIXIMABUM
ENTECAVIRUM	EXISULINDUM	GALSULFASUM
ENZASTAURINUM	EZETIMIBUM	GANSTIGMINUM
EPAFIPASUM	EZLOPITANTUM	GANTACURIUM CHLORIDUM
EPITUMOMABUM CITUXETANUM	FADOLMIDINUM	GANTOFIBANUM
EPITUMOMABUM	FALNIDAMOLUM	GARENOXACINUM
EPLIVANSERINUM	FAMPRONILUM	GARNOCESTIMUM
EPOETINUM ZETA	FANAPANELUM	GAVILIMOMABUM
EPOETINUM DELTA	FANDOSENTANUM	GEFITINIBUM
EPRATUZUMABUM	FARAMPATORUM	GEMCABENUM
EPTAPIRONUM	FARGLITAZARUM	GEMIFLOXACINUM
EPTAPLATINUM	FEBUXOSTATUM	GEMOPATRILATUM
EPTOTERMINUM ALFA	FELOPRENTANUM	GEMTUZUMABUM
ERITORANUM	FESOTERODINUM	GIMATECANUM
ERLIZUMABUM	FIDEXABANUM	GIMERACILUM
ERLOTINIBUM	FIDUXOSINUM	GLUCARPIDASUM
ERTAPENEMUM	FIGOPITANTUM	GOLIMUMABUM
ERTIPROTAFIGUM	FINAFLOXACINUM	HEMOGLOBINUM RAFFIMERUM
ERTUMAXOMAB	FINGOLIMODUM	HEMOGLOBINUM GLUTAMERUM
ESCITALOPRAMUM	FINROZOLUM	HORMONUM PARATHYROIDUM
ESKETAMINUM	FIPAMEZOLUM	IBOCTADEKINUM
ESLICARBAZEPINUM	FIROCOXIBUM	IBRITUMOMABUM TIUXETANUM
ESMIRTAZAPINE	FISPEMIFENUM	IBROLIPIMUM
ESOMEPRAZOLUM	FLINDOKALNERUM	ICARIDINUM
ESONARIMODUM	FLUORESCEINUM LISICOLUM	ICLAPRIMUM
ESOXYBUTYNINUM	FONDAPARINUXUM NATRICUM	ICOFUNGIPENUM
ESZOPICLONUM	FONTOLIZUMABUM	ICOMUCRETUM
ETALOCIBUM	FORODESINUM	ICROCAPTIDUM
ETANERCEPTUM	FOSAMPRENAVIRUM	IDRAPARINUXUM
ETRAVIRINUM	FOSFLUCONAZOLUM	IDREMCINALUM
ETILEVODOPUM	FOSFLURIDINE TIDOXIL	IDRONOXILUM
ETIPREDONIL DICLOACETAS	FOSFRUCTOSUM	IDURSULFASUM
ETORICOXIBUM	FOSVESETUM	IFERANSERINUM

Annex III (continued)

-5-

IGURATIMODUM	LANIQUIDARUM	LUSAPERIDONUM
ILAPRAZOLUM	LAPATINIBUM	LUSUPULTIDUM
ILODECAKINUM	LAPISTERIDUM	MANIFAXINUM
IMATINIBUM	LAQUINIMODUM	MANITIMUS
IMIDAFENACINUM	LARONIDASUM	MANTABEGRONUM
IMIGLITAZARUM	LASOFOXIFENUM	MAPATUMUMAB
IMPLITAPIDUM	LATIDECTINUM (COMPONENT A3)	MARAVIROCUM
INDACATEROLUM	LATIDECTINUM (COMPONENT A4)	MARIBAVIRUM
INDIBULINUM	LECONOTIDUM	MARIMASTAT
INDIPLONUM	LECOZOTAN	MAROPITANTUM
INDISULAMUM	LEMALESOMABUM	MATUZUMABUM
INECALCITOLUM	LEMUTEPORFINUM	MECASERMINUM RINFABAS
INGLIFORIBUM	LENALIDOMIDUM	MECLINERTANTUM
INOTUZUMABUM OZOGAMICINUM	LERDELIMUMABUM	MELDONIUM
INSULINUM GLULISINUM	LERIDISTIMUM	MELEVODOPUM
INSULINUM DETEMIRUM	LESTAURTINIBUM	MEPOLIZUMABUM
IOSIMENOLUM	LETEPRINIMUM	MERIMEPODIBUM
IPRAVACAINUM	LEVMETAMFETAMINUM	METELIMUMABUM
IRAMPANELUM	LEVOLANSOPRAZOLE	METRELEPTINUM
IROFULVENUM	LEVOTOFISOPAMUM	MICAFUNGINUM
IROXANADINUM	LIATERMINUM	MIDAFOTELUM
ISALMADOLUM	LIBIVIRUMABUM	MIDAXIFYLLINUM
ISATORIBINUM	LICARBAZEPINUM	MIDOSTAURINUM
ISEGANANUM	LICOFELONUM	MIGLUSTATUM
ISMOMULTINUM ALFA	LIDORESTATUM	MILATAXELUM
ISPINESIBUM	LINAPRAZANUM	MINOPAFANTUM
ISPRONICLINE	LIRAGLUTIDUM	MINRETUMOMABUM
ISTAROXIME	LIRIMILASTUM	MIRIPLATINUM
ISTRADEFYLLINUM	LITOMEGLOVIRUM	MIROCOCEPTUM
ITRIGLUMIDUM	LIVARAPARINUM CALCIUM	MIROSTIPENUM
ITURELIXUMUM	LIXIVAPTANUM	MITEMCINALUM
IXABEPILONUM	LOMEGUATRIBUM	MITRATAPIDUM
IZONSTERIDUM	LONAFARNIBUM	MITUMOMABUM
LABETUZUMABUM	LOPINAVIRUM	MIVOTILATUM
LABRADIMILUM	LUBAZODONUM	MOROLIMUMABUM
LACOSAMIDUM	LUBIPROSTONUM	MORPHINII GLUCURONIDUM
LADIRUBICINUM	LULICONAZOLUM	MOTEXAFINUM
LADOSTIGILUM	LUMILIXIMABUM	MOZAVAPTANUM
LANICEMINUM	LUMIRACOXIBUM	MOZENAVIRUM
LANIMOSTIMUM	LURASIDONUM	MUBRITINIBUM

Annex III (continued)

-6-

MURAGLITAZARUM	ORTATAXELUM	PERFLUBRODECUM
MURELETECANUM	OSELTAMIVIRUM	PERFLUBUTANUM
NALFURAFINUM	OSEMOZOTANUM	PERFLUTRENUM
NAMINIDILUM	OSPEMIFENUM	PERTUZUMABUM
NASARUPLASUM BETA	OTAMIXABANUM	PERZINFOTELUM
NATALIZUMABUM	OTERACILUM	PEXELIZUMABUM
NAVEGLITAZARUM	OXEGLITAZARUM	PIBOSERODUM
NAVURIDINUM	OZOGAMICINUM	PIBROZELESINUM
NAXIFYLLINUM	PACLITAXELUM POLIGLUMEXUM	PICLOZOTANUM
NEBENTANUM	PACLITAXELUM CERIBAS	PICOPLATINUM
NEBICAPONE	PACTIMIBUM	PIMECROLIMUSUM
NEBOGLAMINUM	PADOPORFIN	PINOKALANTUM
NEMIFITIDUM	PAGIBAXIMAB	PIPENDOXIFENUM
NERAMEXANUM	PALIFERMINUM	PITAVASTATINUM
NERISPIRDINE	PALIPERIDONUM	PITRAKINRUM
NESIRITIDUM	PALIRODEN	PIXANTRONUM
NETOGLITAZONUM	PALIVIZUMABUM	PLERIXAFOR
NETUPITANT	PALOSURANUM	PLEVITREXEDUM
NOLOMIROLUM	PANITUMUMABUM	PLITIDEPSIN
NORELGESTROMINUM	PARECOXIBUM	PONAZURILUM
NORTOPIXANTRONUM	PASCOLIZUMABUM	POSACONAZOLUM
OBLIMERSENUM	PASIREOTIDUM	POSIZOLIDUM
ODIPARCILUM	PATUPILONUM	PRADEFOVIR
OFATUMUMAB	PEFORELIN	PRADOFLOXACINUM
OGLUFANIDUM	PEGACARISTIMUM	PRALATREXATUM
OLAMUFLOXACINUM	PEGAMOTECANUM	PRALNACASANUM
OLANEXIDINUM	PEGAPTANIBUM	PRASUGRELUM
OLCEGEPANTUM	PEGFILFRASTIMUM	PRATOSARTANUM
OLMESARTAN	PEGINTERFERONUM ALFA-2B	PRAZARELIXUM
OLMESARTANUM MEDOXOMILUM	PEGINTERFERONUM ALFA-2A	PRINOMASTATUM
OMACICLOVIRUM	PEGNARTOGRASTIMUM	PRITUMUMABUM
OMALIZUMABUM	PEGSUNERCEPTUM	PROTAMINE SULFATE
OMIGANANUM	PEGVISOMANTUM	PRUVANSERINUM
OMIGAPILUM	PELIGLITAZARUM	PUMAFENTRINUM
OMOCIANINUM	PELITINIBUM	PUMOSETRAGUM
ONERCEPTUM	PELITREXOLUM	RADAFAXINUM
OPAVIRALINUM	PEMAGLITAZARUM	RADEQUINIL
OPEBACANUM	PERAMIVIRUM	RADOTERMINUM
OREGOVOMABUM	PERFLEXANUM	RAFABEGRONUM
ORITAVANCINUM	PERFLISOBUTANUM	RAGAGLITAZARUM

Annex III (continued)

-7-

RALFINAMIDUM	RUPINTRIVIRUM	SULAMSERODUM
RAMELTEONUM	RUPLIZUMABUM	SUMANIROLUM
RANIBIZUMABUM	SABARUBICINUM	SUNITINIB
RANIRESTATUM	SABIPORIDUM	SURINABANT
RANPIRNASUM	SAFINAMIDUM	TABIMORELINUM
RASBURICASUM	SARAKALIMUM	TACAPENEMUM
RAVUCONAZOLUM	SARDOMOZIDUM	TACEDINALINUM
RAXIBACUMABUM	SARIZOTANUM	TADALAFILUM
RAZAXABANUM	SATAVAPTAN	TADEKINIGUM ALFA
REBIMASTATUM	SATRAPLATINUM	TAFENOQUINUM
REGADENOSONUM	SAXAGLIPTINUM	TAFLUPOSIDUM
REGLITAZARUM	SEGESTERONUM	TAFLUPROSTUM
RELCOVAPTANUM	SELAMECTINUM	TALABOSTATUM
REPARIXINUM	SELETRACETAM	TALACTOFERRINUM ALFA
REPIFERMINUM	SELICICLIBUM	TALAGLUMETADUM
REPINOTANUM	SELODENOSONUM	TALAMPANELUM
RESEQUINILUM	SEMAPIMODUM	TALAPORFINUM
RESIQUIMODUM	SEMAXANIBUM	TALIBEGRONUM
RESLIZUMABUM	SEMPARATIDUM	TALIZUMABUM
RETAPAMULINUM	SENAZODANUM	TALNETANTUM
REVAPRAZANUM	SIBENADETUM	TALTOBULINUM
RILPIVIRINUM	SIBROTUZUMABUM	TANAPROGETUM
RIMACALIB	SILODOSINUM	TANDUTINIBUM
RIMEPORIDUM	SIPLIZUMABUM	TANEPTACOGINUM ALFA
RIMONABANTUM	SIPOGLITAZAR	TANOGITRANUM
RISARESTATUM	SIRAMESINUM	TANOMASTATUM
RITOBEGRONUM	SITAMAQUINUM	TAPENTADOLUM
RIVANICLINE	SITAXENTANUM	TAPLITUMOMABUM PAPTOXUM
RIVAROXABANUM	SOBLIDOTINUM	TAPRIZOSINUM
RIVENPROST	SOLABEGRONUM	TARIQUIDARUM
RIVOGLITAZONUM	SOLIFENACINUM	TASIDOTIN
ROBENACOXIBUM	SOLIMASTATUM	TASQUINIMOD
ROFECOXIBUM	SONECLOSANUM	TEBANICLINUM
ROSTAFUROXINUM	SONEPIRAZOLUM	TEBIPENEMUM PIVOXILUM
ROSTAPORFINUM	SORAFENIBUM	TECADENOSONUM
ROSUVASTATINUM	SORAPRAZANUM	TECALCETUM
ROTIGOTINUM	SQUALAMINUM	TECASTEMIZOLUM
ROVELIZUMABUM	STANNSOPORFINUM	TECHNETIUM (99MTC) FANOLESOMABUM
RUBITECANUM	SUFUGOLIXUM	TECHNETIUM (99MTC) NITRIDOCADUM
RUBOXISTAURINUM	SUGAMMADEXUM	TEDUGLUTIDUM

Annex III (continued)

-8-

TEFIBAZUMABUM	TOLVAPTANUM	VARESPLADIBUM
TEGASERODUM	TOMEGLOVIRUM	VATALANIBUM
TEGLICARUM	TONABERSATUM	VEPALIMOMABUM
TELAVANICINUM	TOPILOTAMIDUM	VESTIPITANTUM
TELBERMINUM	TOPIXANTRONUM	VILAZODONUM
TELBIVUDINUM	TORALIZUMABUM	VILDAGLIPTINUM
TELITHROMYCINUM	TORAPSELUM	VISILIZUMABUM
TEMSEROLIMUSUM	TORCETRAPIBUM	VOFOPITANTUM
TENATOPRAZOLUM	TORCITABINUM	VOLOCIXIMAB
TENECTEPLASUM	TOSAGESTINUM	VOLPRISTINUM
TENELIXIMABUM	TOSITUMOMABUM	XIDECAFLURUM
TENIVASTATINUM	TRABECTEDINUM	XIMELAGATRANUM
TENOFOVIRUM	TRAVOPROSTUM	YTTRIUM (90Y) TACATUZUMABUM
TERIFLUNOMIDUM	TRAXOPRODILUM	YTTRIUM (90Y) TACATUZUMAB TETRAXETAN
TERUTROBAN	TRECETILIDUM	ZABOFLOXACIN
TESAGLITAZARUM	TREPROSTINILUM	ZALUTUMUMAB
TESETAXEL	TRETAZICAR	ZANAPEZILUM
TESMILIFENUM	TRIDOLGOSIRUM	ZANOLIMUMABUM
TESOFENSINUM	TRIPLATINUM TETRANITRAS	ZELANDOPAMUM
TETOMILASTUM	TRODUSQUEMINUM	ZIRALIMUMABUM
TETRAXETANUM	TROXACITABINUM	ZONAMPANELUM
TEZACITABINUM	TULATHROMYCINUM A	ZONIPORIDUM
TEZOSENTANUM	TULATHROMYCINUM B	ZOSUQUIDARUM
THROMBOMODULINUM ALFA	UDENAFIL	ZOTICASONUM
TICALOPRIDUM	ULIFLOXACINUM	
TIDEMBERSATUM	ULIPRISNILUM	
TIFENAZOXIDUM	UPIDOSINUM	
TIFUVIRTIDUM	URTOXAZUMABUM	
TIGECYCLINUM	VALATEGRAST	
TILMACOXIBUM	VALDECOXIBUM	
TIMCODARUM	VALOMACICLOVIRUM	
TIPIFARNIBUM	VALOPICITABINE	
TIPLIMOTIDUM	VALROCEMIDUM	
TIPRANAVIRUM	VALRUBICINUM	
TISOCALCITATUM	VALTORCITABINUM	
TIVICICLOVIRUM	VANDETANIBUM	
TOCILIZUMABUM	VANGATALCITUM	
TOCLADESINUM	VAPALIXIMABUM	
TOFIMILASTUM	VARDENAFILUM	
TOLEVAMERUM	VARENICLINUM	

Annex III (continued)

-9-

(3) by inserting in such Table 1, in alphabetical sequence, the following INN and, where specified, the associated CAS registry numbers:

INN	CAS No.	INN	CAS No.
ABAPERIDONE	183849-43-6	ANCESTIM	163545-26-4
ABATACEPT	332348-12-6	ANCRIVIROC	370893-06-4
ABETIMUS	167362-48-3	ANECORTAVE	7753-60-8
ABRINEURIN	178535-93-8	ANIDULAFUNGIN	166663-25-8
ACOLBIFENE	182167-02-8	ANISPERIMUS	170368-04-4
ACOTIAMIDE	185106-16-5	ANTITHROMBIN ALFA	84720-88-7
ADALIMUMAB	331731-18-1	APAQUONE	114560-48-4
ADARGILEUKIN ALFA	250710-65-7	APIXABAN	503612-47-3
ADECATUMUMAB	503605-66-1	APLINDORE (PALINDORE)	189681-70-7
ADEKALANT	227940-00-3	APOLIZUMAB	267227-08-7
ADROGOLIDE	171752-56-0	APRATASTAT	287405-51-0
AFELETECAN	215604-75-4	APREPITANT	170729-80-3
AGALSIDASE BETA	104138-64-9	APRINOCARSEN	151879-73-1
AGALSIDASE ALFA	104138-64-9	ARASERTACONAZOLE	583057-48-1
ALAGEBRIUM CHLORIDE	341028-37-3	ARDENERMIN	305391-49-5
ALAMIFOVIR	193681-12-8	ARFORMOTEROL	67346-49-0
ALBACONAZOLE	187949-02-6	ARIMOCLOMOL	289893-25-0
ALEFACEPT	222535-22-0	ARMODAFINIL	112111-43-0
ALEMCINAL	150785-53-8	ARTEMIFONE	255730-18-8
ALEMTUZUMAB	216503-57-0	ARTEMOTIL	75887-54-6
ALFATRADIOL	57-91-0	ARTENIMOL	81496-81-3
ALFIMEPRASE	259074-76-5	ARUNDIC ACID	185517-21-9
ALGLUCOSIDASE ALFA	420784-05-0	ARZOXIFENE	182133-25-1
ALICAFORSEN	185229-68-9	ASCORBYL GAMOLENATE	109791-32-4
ALILUSEM	144506-11-6	ASELIZUMAB	395639-53-9
ALISKIREN	173334-57-1	ASENAPINE	65576-45-6
ALITRETINOIN	5300-03-8	ASOPRISNIL ECAMATE	222732-94-7
ALTINICLINE	179120-92-4	ASOPRISNIL	199396-76-4
ALVAMELINE	120241-31-8	ATACIGUAT	254877-67-3
ALVIMOPAN	156053-89-3	ATAQUIMAST	182316-31-0
ALVOCIDIB	146426-40-6	ATAZANAVIR	198904-31-3
AMBRISENTAN	177036-94-1	ATILMOTIN	533927-56-9
AMDOXOVIR	145514-04-1	ATOCALCITOL	302904-82-1
AMEDIPASE	151912-11-7	ATOROLIMUMAB	202833-08-7
AMELUBANT	346735-24-8	ATRASENTAN	195733-43-8
AMIGLUMIDE	119363-62-1	AVANAFIL	330784-47-9
AMOTOSALEN	161262-29-9	AVASIMIBE	166518-60-1
AMPRENAVIR	161814-49-9	AVISCUMINE	223577-45-5
ANATIBANT	209733-45-9	AVOSENTAN	290815-26-8
ANATUMOMAB MAFENATOX		AXITIROME	156740-57-7

Annex III (continued)

-10-

INN	CAS No.	INN	CAS No.
AXOMADOL	187219-95-0	CALOXETIC ACID	135306-78-4
BALAGLITAZONE	199113-98-9	CANERTINIB	267243-28-7
BALICATIB	354813-19-7	CANFOSFAMIDE	158382-37-7
BAMIRASTINE	215529-47-8	CANGRELOR	
BANOXANTRONE	136470-65-0	CANTUZUMAB MERTANSINE	400010-39-1
BAPINEUZUMAB	648895-38-9	CAPRAVIRINE	178979-85-6
BARIXIBAT	263562-28-3	CAPROMORELIN	193273-66-4
BARUSIBAN	285571-64-4	CARABERSAT	184653-84-7
BATABULIN	195533-53-0	CARGLUMIC ACID	1188-38-1
BAZEDOXIFENE	198481-32-2	CARICOTAMIDE	64881-21-6
BECAMPANEL	188696-80-2	CARMOTEROL	147568-66-9
BECATECARIN	119673-08-4	CASPOFUNGIN	162808-62-0
BECCALCIDIOL	524067-21-8	CATUMAXOMAB	509077-98-9
BEFETUPITANT	290296-68-3	CEFMATILEN	140128-74-1
BELATACEPT	706808-37-9	CEFOVECIN	234096-34-5
BELIMUMAB	356547-88-1	CEFTOBIPROLE	209467-52-7
BELOTECAN	256411-32-2	CEFTOBIPROLE MEDOCARIL	376653-43-9
BEMINAFIL	566906-50-1	CELECOXIB	169590-42-5
BEMOTRIZINOL	187393-00-6	CERTOLIZUMAB PEGOL	428863-50-7
BERTILIMUMAB	375348-49-5	CETHROMYCIN	205110-48-1
BESILESOMAB	537694-98-7	CETILISTAT	282526-98-1
BEVACIZUMAB	216974-75-3	CETUXIMAB	205923-56-4
BEXAROTENE	153559-49-0	CILENGITIDE	188968-51-6
BEXLOSTERIDE	148905-78-6	CILOMILAST	153259-65-5
BIFARCEPT	163796-60-9	CILUPRE VIR	300832-84-2
BIFEPRUNOX	350992-10-8	CIMICOXIB	265114-23-6
BILASTINE	202189-78-4	CINACALCET	226256-56-0
BIMATOPROST	155206-00-1	CINTREDEKIN BESUDOTOX	372075-36-0
BIMOSIAMOSE	187269-40-5	CIPEMASTAT	190648-49-8
BINETRAKIN	207137-56-2	CIPRALISANT	213027-19-1
BINODENOSON	144348-08-3	CLAMIKALANT	158751-64-5
BISOCTRIZOLE	103597-45-1	CLAZOSENTAN	180384-56-9
BIVATUZUMAB	214559-60-1	CLOFARABINE	123318-82-1
BORTEZOMIB	179324-69-7	COLURACETAM	135463-81-9
BRIVARACETAM	357336-20-0	CONIVAPTAN	210101-16-9
BROSTALLICIN	203258-60-0	CORIFOLLITROPIN ALFA	195962-23-3
BULAQUINE	223661-25-4	CRIDANIMOD	38609-97-1
CADROFLOXACIN	153808-85-6	CROBENETINE	
CALCOBUTROL	151878-23-8	DABIGATRAN	211914-51-1
CALDARET	133804-44-1	DABIGATRAN ETEXILATE	211915-06-9

Annex III (continued)

-11-

INN	CAS No.	INN	CAS No.
DABUZALGRON	219311-44-1	DIRLOTAPIDE	481658-94-0
DACINOSTAT	404951-53-7	DISERMOLIDE	127943-53-7
DAGLUTRIL	182821-27-8	DISUFENTON SODIUM	168021-79-2
DALBAVANCIN	171500-79-1	DOFEQUIDAR	129716-58-1
DAPICLERMINE	444069-80-1	DONITRIPTAN	170912-52-4
DAPIVIRINE	244767-67-7	DORAMAPIMOD	285983-48-4
DARBEOETIN ALFA	209810-58-2	DORANIDAZOLE	149838-23-3
DARBUFELONE	139226-28-1	DORIPENEM	148016-81-3
DARUNAVIR	206361-99-1	DOXERCALCIFEROL	54573-75-0
DARUSENTAN	171714-84-4	DROTRECOGIN ALFA (ACTIVATED)	98530-76-8
DASANTAFIL	569351-91-3	ECALCIDENE	150337-94-3
DAVASAICIN	147497-64-1	ECALLANTIDE	460738-38-9
DAXALIPRAM	189940-24-7	ECOPIPAM	112108-01-7
DEFERASIROX	201530-41-8	ECOPLADIB	381683-92-7
DEFERITRIN	239101-33-8	ECRAPROST	136892-64-3
DEFOSLIMOD	171092-39-0	ECROMEXIMAB	292819-64-8
DEGARELIX	214766-78-6	ECULIZUMAB	219685-50-4
DELIGOPARIN SODIUM	9041-08-1	EDAGLITAZONE	213411-83-7
DELMITIDE	287096-87-1	EDIFOLIGIDE	328538-04-1
DELUCEMINE	186495-49-8	EDODEKIN ALFA	187348-17-0
DENUFOSOL	211448-85-0	EDONENTAN	210891-04-6
DEPELESTAT	506433-25-6	EDOTECARIN	174402-32-5
DEPREOTIDE	161982-62-3	EDOTREOTIDE	204318-14-9
DERACOXIB	169590-41-4	EDRATIDE	433922-67-9
DERSALAZINE	188913-58-8	EDRONOCAINE	190258-12-9
DESLORATADINE	100643-71-8	EFALIZUMAB	214745-43-4
DESMENINOL	583-91-5	EFAPROXIRAL	131179-95-8
DESMOTEPLASE	145137-38-8	EFIPLADIB	381683-94-9
DESVENLAFAXINE	93413-62-8	EFLUCIMIBE	202340-45-2
DETIVICICLOVIR	220984-26-9	EGANOPROST	63266-93-3
DEUTOLPERISONE	474641-19-5	EGLUMETAD (EGLUMEGAD)	176199-48-7
DEXBUDESONIDE	51372-29-3	ELAROFIBAN	198958-88-2
DEXLANSOPRAZOLE	138530-94-6	ELOMOTECAN	220998-10-7
DEXMETHYLPHENIDATE	40431-64-9	ELSILIMOMAB	468715-71-1
DEXTIOPRONIN	29335-92-0	ELVUCITABINE	181785-84-2
DEXTOFISOPAM	82059-50-5	ELZASONAN	361343-19-3
DIANICLINE	292634-27-6	EMBECONAZOLE	329744-44-7
DIBOTERMIN ALFA	246539-15-1	EMFILERMIN	159075-60-2
DIFLOMOTECAN	220997-97-7	EMIVIRINE	149950-60-7
DIQUAFOSOL	59885-21-6	EMODEPSIDE	155030-63-0

Annex III (continued)

-12-

INN	CAS No.	INN	CAS No.
EMTRICITABINE	143491-57-0	EVEROLIMUS	159351-69-6
ENECADIN	259525-01-4	EXATECAN	171335-80-1
ENFUVRTIDE	159519-65-0	EXATECAN ALIDEXIMER	
ENIPORIDE	176644-21-6	EXBIVIRUMAB	569658-80-6
ENRASENTAN	167256-08-8	EXENATIDE	141758-74-9
ENTECAVIR	142217-69-4	EXISULIND	59973-80-7
ENZASTAURIN	170364-57-5	EZETIMIBE	163222-33-1
EPAFIPASE	208576-22-1	EZLOPITANT	147116-64-1
EPITUMOMAB CITUXETAN	263547-71-3	FADOLMIDINE (RADOLMIDINE)	189353-31-9
EPITUMOMAB		FALNIDAMOL	196612-93-8
EPLIVANSERIN	130579-75-8	FAMPRONIL	134183-95-2
EPOETIN DELTA	261356-80-3	FANAPANEL	161605-73-8
EPOETIN ZETA	604802-70-2	FANDOSANTAN	221241-63-0
EPRATUZUMAB	205923-57-5	FARAMPATOR	211735-76-1
EPTAPIRONE	179756-85-5	FARGLITAZAR	196808-45-4
EPTAPLATIN	146665-77-2	FEBUXOSTAT	144060-53-7
EPTOTERMIN ALFA	129805-33-0	FELOPRENTAN	204267-33-4
ERITORAN	185955-34-4	FESOTERODINE	286930-03-8
ERLIZUMAB	211323-03-4	FIDEXABAN	183305-24-0
ERLOTINIB	183321-74-6	FIDUXOSIN	208993-54-8
ERTAPENEM	153832-46-3	FIGOPITANT	502422-74-4
ERTIPROTAFOB	251303-04-5	FINAFLOXACIN	209342-40-5
ERTUMAXOMAB	509077-99-0	FINGOLIMOD	162359-55-9
ESCITALOPRAM	128196-01-0	FINROZOLE	160146-17-8
ESKETAMINE	33643-46-8	FIPAMEZOLE	150586-58-6
ESLICARBAZEPINE	104746-04-5	FIROCOXIB	189954-96-9
ESMIRTAZAPINE	61337-87-9	FISPEMIFENE	341524-89-8
ESOMEPRAZOLE	119141-88-7	FLINDOKALNER	187523-35-9
ESONARIMOD	101973-77-7	FLUORESCHEIN LISICOL	140616-46-2
ESOXYBUTYNIN	119618-22-3	FONDAPARINUX SODIUM	114870-03-0
ESZOPICLONE	138729-47-2	FONTOLIZUMAB	326859-36-3
ETALOCIB	161172-51-6	FORODESINE	209799-67-7
ETANERCEPT	185243-69-0	FOSAMPRENAVIR	226700-79-4
ETILEVODOPA	37178-37-3	FOSFLUCONAZOLE	194798-83-9
ETIPREDNOL DICLOACETATE	199331-40-3	FOSFLURIDINE TIDOXIL	174638-15-4
ETORICOXIB	202409-33-4	FOSFRUCTOSE	488-69-7
ETRAVIRINE	269055-15-4	FOSVESET	193901-91-6
ETRICIGUAT	402595-29-3	FRAKEFAMIDE	188196-22-7
EUFAUSERASE		FRESELESTAT	208848-19-5
EVERNIMICIN	109545-84-8	GADOCOLETIC ACID	280776-87-6

Annex III (continued)

-13-

INN	CAS No.	INN	CAS No.
GADODENTERATE	544697-52-1	IMIDAFENACIN	170105-16-5
GADOFOSVESET	193901-90-5	IMIGLITAZAR	250601-04-8
GADOMELITOL	227622-74-4	IMPLITAPIDE	177469-96-4
GALARUBICIN	140637-86-1	INDACATEROL	312753-06-3
GALIXIMAB	357613-77-5	INDIBULIN	204205-90-3
GALSULFASE	552858-79-4	INDIPLON	325715-02-4
GANSTIGMINE		INDISULAM	165668-41-7
GANTACURIUM CHLORIDE	213998-46-0	INECALCITOL	163217-09-2
GANTOFIBAN	183547-57-1	INGLIFORIB	186392-65-4
GARENOXACIN	194804-75-6	INOTUZUMAB OZOGAMICIN	635715-01-4
GARNOCESTIM	246861-96-1	INSULIN DETEMIR	169148-63-4
GAVILIMOMAB	244096-20-6	INSULIN GLULISINE	207748-29-6
GEFITINIB	184475-35-2	IOSIMENOL	181872-90-2
GEMCABENE	183293-82-5	IPRAVACAINE	166181-63-1
GEMIFLOXACIN	204519-64-2	IRAMPANEL	206260-33-5
GEMOPATRILAT	160135-92-2	IROFULVEN	158440-71-2
GEMTUZUMAB	220578-59-6	IROXANADINE	276690-58-5
GIMATECAN	292618-32-7	ISALMADOL	269079-62-1
GIMERACIL	103766-25-2	ISATORIBINE	122970-40-5
GLUCARPIDASE	9074-87-7	ISEGANAN	257277-05-7
GOLIMUMAB	476181-74-5	ISMOMULTIN ALFA	457913-93-8
HEMOGLOBIN GLUTAMER		ISPINESIB	336113-53-2
HEMOGLOBIN RAFFIMER	197462-97-8	ISPRONICLINE	252870-53-4
IBOCTADEKIN	479198-61-3	ISTAROXIME	203737-93-3
IBRITUMOMAB TIUXETAN	206181-63-7	ISTRADEFYLLINE	155270-99-8
IBROLIPIM	133208-93-2	ITRIGLUMIDE	201605-51-8
ICARIDIN	119515-38-7	ITURELIX	112568-12-4
ICLAPRIM	192314-93-5	IXABEPILONE	219989-84-1
ICOFUNGIPEN	198022-65-0	IZONSTERIDE	176975-26-1
ICOMUCRET	54845-95-3	LABETUZUMAB	219649-07-7
ICROCAPTIDE	169543-49-1	LABRADIMIL	159768-75-9
IDRAPARINUX SODIUM	149920-56-9	LACOSAMIDE (ERLOSAMIDE)	175481-36-4
IDREMCINAL	110480-13-2	LADIRUBICIN	171047-47-5
IDRONOXIL	81267-65-4	LADOSTIGIL	209394-27-4
IDURSULFASE (IDUSULFASE)	50936-59-9	LANICEMINE	153322-05-5
IFERANSERIN	58754-46-4	LANIMOSTIM	117276-75-2
IGURATIMOD	123663-49-0	LANIQUIDAR	197509-46-9
ILAPRAZOLE	172152-36-2	LAPATINIB	231277-92-2
ILODECAKIN	149824-15-7	LAPISTERIDE	142139-60-4
IMATINIB	152459-95-5	LAQUINIMOD	248281-84-7

Annex III (continued)

-14-

INN	CAS No.	INN	CAS No.
LARONIDASE	210589-09-6	MANITIMUS	202057-76-9
LASOFOXIFENE	180916-16-9	MANTABEGRON	36144-08-8
LATIDECTIN A3	371918-51-3	MAPATUMUMAB	658052-09-6
LATIDECTIN A4	371918-44-4	MARAVIROC	376348-65-1
LECONOTIDE	247207-64-3	MARIBAVIR	176161-24-3
LECOZOTAN	434283-16-6	MARIMASTAT	154039-60-8
LEMALESOMAB	250242-54-7	MAROPITANT	147116-67-4
LEMUTEPORFIN	215808-49-4	MATUZUMAB	339186-68-4
LENALIDOMIDE	191732-72-6	MECASERMIN RINFABATE	478166-15-3
LERDELIMUMAB	285985-06-0	MECLINERTANT (REMINERTANT)	146362-70-1
LERIDISTIM	193700-51-5	MELDONIUM	76144-81-5
LESTAURTINIB	111358-88-4	MELEVODOPA	7101-51-1
LETEPRINIM	138117-50-7	MEPOLIZUMAB	196078-29-2
LEVMETAMFETAMINE	33817-09-3	MERIMEPODIB	198821-22-6
LEVOLANSOPRAZOLE	138530-95-7	METELIMUMAB	272780-74-2
LEVOTOFISOPAM	82059-51-6	METRELEPTIN	186018-45-1
LIATERMIN	188630-14-0	MICAFUNGIN	235114-32-6
LIBIVIRUMAB	569658-79-3	MIDAFOTEL	117414-74-1
LICARBAZEPINE	29331-92-8	MIDAXIFYLLINE	151159-23-8
LICOFELONE	156897-06-2	MIDOSTAURIN	120685-11-2
LIDADRONIC ACID	63132-38-7	MIGLUSTAT	72599-27-0
LIDORESTAT	245116-90-9	MILATAXEL	393101-41-2
LINAPRAZAN	248919-64-4	MINOPAFANT	128420-61-1
LIRAGLUTIDE	204656-20-2	MINRETUMOMAB	195189-17-4
LIRIMILAST	329306-27-6	MIRIPLATIN	141977-79-9
LITOMEGLOVIR	321915-31-5	MIROCOCEPT	507453-82-9
LIVARAPARIN CALCIUM		MIROSTIPEN	244130-01-6
LIXIVAPTAN	168079-32-1	MITEMCINAL	154738-42-8
LOMEGUATRIB	192441-08-0	MITRATAPID	179602-65-4
LONAFARNIB	193275-84-2	MITUMOMAB	216503-58-1
LOPINA VIR	192725-17-0	MIVOTILATE	130112-42-4
LUBAZODONE	161178-07-0	MOROLIMUMAB	202833-07-6
LUBIPROSTONE	333963-40-9	MORPHINE GLUCURONIDE	20290-10-2
LULICONAZOLE	187164-19-8	MOTEXAFIN	189752-49-6
LUMILIXIMAB	357613-86-6	MOZAVAPTAN	137975-06-5
LUMIRACOXIB	220991-20-8	MOZENAVIR	174391-92-5
LURASIDONE	367514-87-2	MUBRITINIB	366017-09-6
LUSAPERIDONE	214548-46-6	MURAGLITAZAR	331741-94-7
LUSUPULTIDE	200074-80-2	MURELETECAN	246527-99-1
MANIFAXINE	135306-39-7	NALFURAFINE	152657-84-6

Annex III (continued)

-15-

INN	CAS No.	INN	CAS No.
NAMINIDIL	220641-11-2	OSPEMIFENE	128607-22-7
NASARUPLASE BETA	136653-69-5	OTAMIXABAN	193153-04-7
NATALIZUMAB	189261-10-7	OTERACIL	937-13-3
NAVEGLITAZAR	476436-68-7	OXEGLITAZAR	280585-34-4
NAVURIDINE	84472-85-5	OZOGAMICIN	
NAXIFYLLINE	166374-49-8	PACLITAXEL POLIGLUMEX	263351-82-2
NEBENTAN	403604-85-3	PACLITAXEL CERIBATE	186040-50-6
NEBICAPONE	274925-86-9	PACTIMIBE	189198-30-9
NEBOGLAMINE (NEBOSTINEL)	163000-63-3	PADOPORFIN	274679-00-4
NEMIFITIDE	173240-15-8	PAGIBAXIMAB	595566-61-3
NERAMEXANE	219810-59-0	PALIFERMIN	162394-19-6
NERISPIRDINE	119229-65-1	PALIPERIDONE	144598-75-4
NESIRITIDE	124584-08-3	PALIRODEN	188396-77-2
NETOGLITAZONE	161600-01-7	PALIVIZUMAB	188039-54-5
NETUPITANT	290297-26-6	PALOSURAN	540769-28-6
NOLOMIROLE	90060-42-7	PANITUMUMAB	339177-26-3
NORELGESTROMIN	53016-31-2	PARATHYROID HORMONE	345663-45-8
NORTOPIXANTRONE	156090-17-4	PARECOXIB	198470-84-7
OBLIMERSEN	190977-41-4	PASCOLIZUMAB	331243-22-2
ODIPARCIL	137215-12-4	PASIREOTIDE	396091-73-9
OFATUMUMAB	679818-59-8	PATUPILONE	152044-54-7
OGLUFANIDE	38101-59-6	PEFORELIN	147859-97-0
OLAMUFLOXACIN	167887-97-0	PEGACARISTIM	187139-68-0
OLANEXIDINE	146510-36-3	PEGAMOTECAN	203066-49-3
OLCEGEPANT	204697-65-4	PEGAPTANIB	
OLMESARTAN MEDOXOMIL (OLME	144689-63-4	PEGFILGRASTIM	208265-92-3
OLMESARTAN	144689-24-7	PEGINTERFERON ALFA-2A	198153-51-4
OMACICLOVIR	124265-89-0	PEGINTERFERON ALFA-2B	215647-85-1
OMALIZUMAB	242138-07-4	PEGNARTOGRASTIM	204565-76-4
OMIGANAN	204248-78-2	PEGSUNERCEPT	330988-75-5
OMIGAPIL	181296-84-4	PEGVISOMANT	218620-50-9
OMOCIANINE	154082-13-0	PELIGLITAZAR	331744-64-0
ONERCEPT	199685-57-9	PELITINIB	257933-82-7
OPAVIRALINE	178040-94-3	PELITREXOL	446022-33-9
OPEBACAN	206254-79-7	PEMAGLITAZAR	496050-39-6
OREGOVOMAB	213327-37-8	PERAMIVIR	229614-55-5
ORITAVANCIN	171099-57-3	PERFLEXANE	355-42-0
ORTATAXEL	186348-23-2	PERFLISOBUTANE	354-92-7
OSELTAMIVIR	196618-13-0	PERFLUBRODEC	307-43-7
OSEMOZOTAN	137275-81-1	PERFLUBUTANE	355-25-9

Annex III (continued)

-16-

INN	CAS No.	INN	CAS No.
PERFLUTREN	76-19-7	RANIBIZUMAB	347396-82-1
PERTUZUMAB	380610-27-5	RANIRESTAT	147254-64-6
PERZINFOTEL	144912-63-0	RANPIRNASE	196488-72-9
PEXELIZUMAB	219685-93-5	RASBURICASE	134774-45-1
PIBOSEROD	152811-62-6	RAVUCONAZOLE	182760-06-1
PIBROZELESIN	154889-68-6	RAXIBACUMAB	565451-13-0
PICLOZOTAN	182415-09-4	RAZAXABAN	218298-21-6
PICOPLATIN	181630-15-9	REBIMASTAT	259188-38-0
PIMECROLIMUS	137071-32-0	REGADENOSON	313348-27-5
PINOKALANT	149759-26-2	REGLITAZAR	170861-63-9
PIPENDOXIFENE	198480-55-6	RELCOVAPTAN	150375-75-0
PITAVASTATIN (ITAVASTATIN)	147511-69-1	REPARIXIN	266359-83-5
PITRAKINRA		REPIFERMIN	219527-63-6
PIXANTRONE	144510-96-3	REPINOTAN	144980-29-0
PLERIXAFOR	110078-46-1	RESIQUIMOD	144875-48-9
PLEVITREXED	153537-73-6	RESLIZUMAB	241473-69-8
PLITIDEPSIN	137219-37-5	RETAPAMULIN	224452-66-8
PONAZURIL	69004-04-2	REVAPRAZAN	199463-33-7
POSACONAZOLE	171228-49-2	RILPIVIRINE	500287-72-9
POSIZOLID	252260-02-9	RIMACALIB	215174-50-8
PRADEFOVIR	625095-60-5	RIMEPORIDE	187870-78-6
PRADOFLOXACIN	195532-12-8	RIMONABANT	168273-06-1
PRALATREXATE	146464-95-1	RISARESTAT	79714-31-1
PRALNACASAN	192755-52-5	RITOBEGRON	255734-04-4
PRASUGREL	150322-43-3	RIVANICLINE	15585-43-0
PRATOSARTAN	153804-05-8	RIVAROXABAN	366789-02-8
PRAZARELIX	134457-28-6	RIVENPROST	256382-08-8
PRINOMASTAT	192329-42-3	RIVOGLITAZONE	185428-18-6
PRITUMUMAB	499212-74-7	ROBENACOXIB	220991-32-2
PROTAMINE SULFATE	9009-65-8	ROFECOXIB	162011-90-7
PRUVANSERIN	443144-26-1	ROSTAFUROXIN	156722-18-8
PUMAFENTRINE	207993-12-2	ROSTAPORFIN	284041-10-7
PUMOSETRAG	153062-94-3	ROSUVASTATIN	287714-41-4
RADAFAXINE	192374-14-4	ROTIGOTINE	99755-59-6
RADEQUINIL (RESEQUINIL)	219846-31-8	ROVELIZUMAB	197099-66-4
RADOTERMIN	575458-75-2	RUBITECAN	91421-42-0
RAFABEGRON	244081-42-3	RUBOXISTAURIN	169939-94-0
RAGAGLITAZAR	222834-30-2	RUPINTRIVIR	223537-30-2
RALFINAMIDE	133865-88-0	RUPLIZUMAB	220651-94-5
RAMELTEON	196597-26-9	SABARUBICIN	211100-13-9

Annex III (continued)

-17-

INN	CAS No.	INN	CAS No.
SABIPORIDE	324758-66-9	SUMANIROLE	179386-43-7
SAFINAMIDE	133865-89-1	SUNITINIB	557795-19-4
SALCAPROZIC ACID	183990-46-7	SURINABANT	288104-79-0
SALCLOBUZIC ACID	387825-03-8	TABIMORELIN	193079-69-5
SARAKALIM	148430-28-8	TACAPENEM	193811-33-5
SARDOMOZIDE	149400-88-4	TACEDINALINE	112522-64-2
SARIZOTAN	351862-32-3	TADALAFIL	171596-29-5
SATAVAPTAN	185913-78-4	TADEKINIG ALFA	220712-29-8
SATRAPLATIN	129580-63-8	TAFENOQUINE	106635-80-7
SAXAGLIPTIN	361442-04-8	TAFLUPOSIDE	179067-42-6
SEGESTERONE	7690-08-6	TAFLUPROST	209860-87-7
SELAMECTIN	165108-07-6	TALABOSTAT	149682-77-9
SELETRACETAM	357336-74-4	TALACTOFERRIN ALFA	308240-58-6
SELICICLIB	186692-46-6	TALAGLUMETAD	441765-98-6
SELODENOSON	110299-05-3	TALAMPANEL	161832-65-1
SEMAPIMOD	352513-83-8	TALAPORFIN	110230-98-3
SEMAXANIB	194413-58-6	TALIBEGRON	146376-58-1
SEMPARATIDE	154906-40-8	TALIZUMAB	380610-22-0
SENAZODAN	98326-32-0	TALNETANT	174636-32-9
SIBENADET	154189-40-9	TALTOBULIN	228266-40-8
SIBROTUZUMAB	216669-97-5	TANAPROGET	304853-42-7
SILODOSIN	160970-54-7	TANDUTINIB	387867-13-2
SIPLIZUMAB	288392-69-8	TANEPTACOGIN ALFA	465540-87-8
SIPOGLITAZAR	342026-92-0	TANOGITRAN	637328-69-9
SIRAMESINE	147817-50-3	TANOMASTAT	179545-77-8
SITAMAQUINE	57695-04-2	TAPENTADOL	175591-23-8
SITAXENTAN	184036-34-8	TAPLITUMOMAB PAPTOX	235428-87-2
SOBLIDOTIN	149606-27-9	TAPRIZOSIN	210538-44-6
SOLABEGRON	252920-94-8	TARIQUIDAR	206873-63-4
SOLIFENACIN	242478-37-1	TASIDOTIN	192658-64-3
SOLIMASTAT		TASQUINIMOD	254964-60-8
SONECLOSAN	3380-30-1	TEBANICLINE	198283-73-7
SONEPIPRAZOLE	170858-33-0	TEBIPENEM PIVOXIL (TEBIPENEM)	161715-24-8
SORAFENIB	284461-73-0	TECADENOSON	204512-90-3
SORAPRAZAN	261944-46-1	TECALCET	148717-54-8
SQUALAMINE	148717-90-2	TECASTEMIZOLE	75970-99-9
STANNSOPORFIN	106344-20-1	TECHNETIUM (99MTC) FANOLESOMA	225239-31-6
SUFUGOLIX	308831-61-0	TECHNETIUM (99MTC) NITRIDOCADÉ	131608-78-1
SUGAMMADEX	343306-71-8	TEDUGLUTIDE	287714-30-1
SULAMSEROD		TEFIBAZUMAB	521079-87-8

Annex III (continued)

-18-

INN	CAS No.	INN	CAS No.
TEGASEROD	145158-71-0	TONABERSAT	175013-84-0
TEGLICAR	250694-07-6	TOPILOTAMIDE	260980-89-0
TELAVANCIN	372151-71-8	TOPIXANTRONE	156090-18-5
TELBERMIN	205887-54-3	TORALIZUMAB	252662-47-8
TELBIVUDINE	3424-98-4	TORAPSEL	204658-47-9
TELITHROMYCIN	173838-31-8	TORCETRAPIB	262352-17-0
TEMSIROLIMUS	162635-04-3	TORCITABINE	40093-94-5
TENATOPRAZOLE	113712-98-4	TOSAGESTIN	110072-15-6
TENECTEPLASE	191588-94-0	TOSITUMOMAB	192391-48-3
TENELIXIMAB	299423-37-3	TRABECTEDIN	114899-77-3
TENIVASTATIN	121009-77-6	TRAVOPROST	157283-68-6
TENOFOVIR	147127-20-6	TRAXOPRODIL	134234-12-1
TERIFLUNOMIDE	108605-62-5	TRECETILIDE	180918-68-7
TERUTROBAN	165538-40-9	TREPROSTINIL	81846-19-7
TESAGLITAZAR	251565-85-2	TRETAZICAR	21919-05-1
TESETAXEL	333754-36-2	TRIDOLGOSIR	72741-87-8
TESMILIFENE	98774-23-3	TRIPLATIN TETRANITRATE	172903-00-3
TESOFENSINE	195875-84-4	TRODUSQUEMINE	186139-09-3
TETOMILAST	145739-56-6	TROXACITABINE	145918-75-8
TEZACITABINE	130306-02-4	TULATHROMYCIN A	217500-96-4
TEZOSENTAN	180384-57-0	TULATHROMYCIN B	280755-12-6
THROMBOMODULIN ALFA	120313-91-9	UDENAFIL	268203-93-6
TICALOPRIDE	202590-69-0	ULIFLOXACIN	112984-60-8
TIDEMBERSAT	175013-73-7	ULIPRISNIL	159811-51-5
TIFENAZOXIDE	279215-43-9	UPIDOSIN	152735-23-4
TIFUVIRTIDE	251562-00-2	URTOXAZUMAB	502496-16-4
TIGECYCLINE	220620-09-7	VALATEGRAST	220847-86-9
TILMACOXIB	180200-68-4	VALDECOXIB	181695-72-7
TIMCODAR	179033-51-3	VALOMACICLOVIR	195157-34-7
TIPIFARNIB	192185-72-1	VALOPICITABINE	640281-90-9
TIPLIMOTIDE	178823-49-9	VALROCEMIDE	92262-58-3
TIPRANAVIR	174484-41-4	VALRUBICIN	56124-62-0
TISOCALCITATE	156965-06-9	VALTORCITABINE	380886-95-3
TIVICICLOVIR	103024-93-7	VANDETANIB	338992-00-0
TOCILIZUMAB	375823-41-9	VANGATALCITE	12539-23-0
TOCLADESINE	41941-56-4	VAPALIXIMAB	336801-86-6
TOFIMILAST	185954-27-2	VARDENAFIL	224785-90-4
TOLEVAMER	28210-41-5	VARENICLINE	249296-44-4
TOLVAPTAN	150683-30-0	VARESPLADIB	172732-68-2
TOMEGLOVIR	233254-24-5	VATALANIB	212141-54-3

Annex III (continued)

-19-

INN	CAS No.		
VEPALIMOMAB	195158-85-1		
VERTEPORFIN	129497-78-5		
VESTIPITANT	334476-46-9		
VILAZODONE	163521-12-8		
VILDAGLIPTIN	274901-16-5		
VISILIZUMAB	219716-33-3		
VOFOPITANT	168266-90-8		
VOLOCIXIMAB	558480-40-3		
VOLPRISTIN	21102-49-8		
XIDECAFLUR	207916-33-4		
XIMELAGATRAN	192939-46-1		
YTTRIUM (90Y) TACATUZUMAB TET	476413-07-7		
ZABOFLOXACIN	219680-11-2		
ZALUTUMUMAB	667901-13-5		
ZANAPEZIL	142852-50-4		
ZANOLIMUMAB	652153-01-0		
ZELANDOPAM	139233-53-7		
ZIRALIMUMAB			
ZONAMPANEL	210245-80-0		
ZONIPORIDE	241800-98-6		
ZOSUQUIDAR	167354-41-8		
ZOTICASONE			

EXECUTIVE OFFICE OF THE PRESIDENT
THE UNITED STATES TRADE REPRESENTATIVE
WASHINGTON, D.C. 20508

DEC 18 2008

The Honorable Shara L. Aranoff
Chairman
U.S. International Trade Commission
500 E Street, SW
Washington, DC 20436

Dear Chairman Aranoff:

The U.S. International Trade Commission (Commission) played an important role in supporting the negotiation of the Dominican Republic-Central America-United States Free Trade Agreement (CAFTA-DR). I appreciate the tremendous efforts the Commission made in connection with this agreement and the significant assistance that the Commission continues to provide in support of the Administration's other major negotiations.

President Bush is expected to proclaim preferential tariff treatment to implement the CAFTA-DR with respect to Costa Rica effective as of January 1, 2009. USTR staff has worked closely with Commission staff on drafts of the modifications to the Harmonized Tariff Schedule of the United States (HTSUS) that the President will proclaim to implement the CAFTA-DR with respect to Costa Rica. The texts of these tariff modifications are enclosed.

Accordingly, I request that the Commission publish as a formal Commission publication those changes to the HTSUS that the President will proclaim to implement the CAFTA-DR with respect to Costa Rica. I understand that the Commission will make this publication available to the public and that the proclaimed tariff modifications will be posted to the Commission's website. In addition, the Federal Depository Libraries will receive this information. I request that the Commission publish this document and transmit copies of the publication to the Office of the U.S. Trade Representative as quickly as possible.

The Commission's willingness to use the most efficient, cost-effective means to inform the public of proclaimed tariff modifications greatly assists our efforts to put this important agreement into force.

Sincerely,



Susan C. Schwab

Enclosure

CHAIRMAN



UNITED STATES INTERNATIONAL TRADE COMMISSION

WASHINGTON, D.C. 20436

December 22, 2008

The Honorable Susan C. Schwab
United States Trade Representative
600 Seventh Street, NW
Washington, DC 20508

Dear Ambassador Schwab:

Thank you for your letter of December 18, 2008, requesting that the Commission publish the text of the modifications to the Harmonized Tariff Schedule of the United States that the President will proclaim in connection with the entry into force of the Central America Free Trade Agreement with respect to Costa Rica.

We are publishing the text of these annexes as Commission Publication No. 4038 and will place the publication on the Commission's internet site as soon as possible. The Commission will make the document available to the public and to U.S. Government depository libraries as you have requested.

If we may be of further assistance in this matter, please do not hesitate to contact us.

Sincerely,

A handwritten signature in black ink that reads "Shara L. Aranoff". The signature is written in a cursive style with a large, prominent "S" and "A".

Shara L. Aranoff